News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|December 24, 2022

Holiday Mental Health Tips From Santa

Author(s)Psychiatric Times Editors

Incoming from the big man in red...

Our friends at Drug Topics got the opportunity to speak with Santa on how he keeps calm during the tough holiday season.

How are you staying cool and collected this Christmas?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

1 expert is featured in this series.

The Switch Study: Why a New Mechanism Demands a New Approach

ByDavid Walling, PhD

June 17th 2026

Psychiatric Times Experts Weight in on FDA Advisory Decision for PTSD

Psychiatric Times Experts Weigh in on FDA Advisory Decision for PTSD

ByJohn J. Miller, MD,Michael Asbach, DMSc, PA-C, Psych-CAQ,Erin Crown, MHS, PA-C, Psych-CAQ,Leah Kuntz

July 18th 2025

New Africa /Adobestock

Poster at APA Annual Meeting Explores the Use of GLP-1 Agonists for Antipsychotic-Associated Metabolic Issues

ByAmir Meftah, MD,Heidi Anne Duerr, MPH

May 18th 2025

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD

ByMehdi Farokhnia, MD, MPH

June 5th 2024

Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.

Research and Opportunities at the 2024 ASCP Annual Meeting

ByErin Crown, MHS, PA-C, Psych-CAQ

May 30th 2024

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS

Metabolic Risk, Residual Insomnia, and Seltorexant